Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Assets (2021 - 2025)

Historic Current Assets for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $338.9 million.

  • ARS Pharmaceuticals' Current Assets rose 6229.93% to $338.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $338.9 million, marking a year-over-year increase of 6229.93%. This contributed to the annual value of $334.3 million for FY2024, which is 4426.31% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Current Assets of $338.9 million as of Q3 2025, which was up 6229.93% from $281.4 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Current Assets' 5-year high stood at $378.3 million during Q1 2021, with a 5-year trough of $60.7 million in Q4 2021.
  • For the 5-year period, ARS Pharmaceuticals' Current Assets averaged around $268.1 million, with its median value being $267.3 million (2023).
  • Within the past 5 years, the most significant YoY rise in ARS Pharmaceuticals' Current Assets was 35726.99% (2022), while the steepest drop was 3092.78% (2022).
  • Over the past 5 years, ARS Pharmaceuticals' Current Assets (Quarter) stood at $60.7 million in 2021, then soared by 357.27% to $277.7 million in 2022, then dropped by 16.56% to $231.7 million in 2023, then soared by 44.26% to $334.3 million in 2024, then rose by 1.37% to $338.9 million in 2025.
  • Its Current Assets was $338.9 million in Q3 2025, compared to $281.4 million in Q2 2025 and $303.9 million in Q1 2025.